share_log

Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection

Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection

武田公司的血管水腫藥物顯示出對抗新冠肺炎感染的良好效果
Benzinga Real-time News ·  2022/03/08 08:56
  • Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID-19 in lab experiments.
  • Icatibant blocks a protein called bradykinin receptor b2 in the so-called kinin system. 
  • The ACE2 protein regulates the protein on cell surfaces, which the coronavirus uses as a gateway for infection. 
  • In lab testing, repeated dosing of icatibant did not stop coronavirus infection completely but reduced the severity of infection. 
  • While a low concentration of 1 nM B2R-antagonist was sufficient to reduce viral RNA in primary bronchial epithelial cells when cells were treated pre-infection, 100 nM B2R-antagonist was required to this effect when cells were treated post-infection. 
  • In addition, the significant reduction in virus load as determined by PCR tapered off after 96 hours. 
  • But on the other hand, the B2R-antagonist icatibant used in this study has a short half-life in the human body.
  • The researchers noted that pharmacological tolerance to interference at receptor level might explain why the effect reached significance after 6 hours but did not persist. 
  • Therefore, it may be required to administer higher doses of the B2R-antagonist to COVID-19 patients a few times per day to inhibit viral replication in the long term.
  • Price Action: TAK shares are down 1.62% at $14.58 during the premarket session on the last check Tuesday.
  • 武田藥品工業株式會社(紐約證券交易所股票代碼：TAK)Firazyr(Icatibant)用於治療一種名為血管水腫的血管疾病，在實驗室實驗中顯示出作為新冠肺炎治療藥物的前景。
  • Icatibant阻斷了所謂激肽系統中一種名為緩激肽受體b2的蛋白質。
  • ACE2蛋白調節細胞表面的蛋白質，冠狀病毒將其用作感染的門户。
  • 在實驗室檢測中，反覆服用icatibant並沒有完全阻止冠狀病毒的感染，但減輕了感染的嚴重程度。
  • 當細胞感染前處理時，低濃度的1 nM B2R拮抗劑足以減少原代支氣管上皮細胞中的病毒RNA，而感染後處理細胞時則需要100 nM的B2R拮抗劑。
  • 此外，通過PCR檢測病毒載量的顯著降低在96小時後逐漸消失。
  • 但另一方面，本研究中使用的B2R拮抗劑在人體內的半衰期很短。
  • 研究人員指出，受體水平對幹擾的藥理學耐受性可能解釋了為什麼這種效果在6小時後達到顯著水平，但並不持續。
  • 因此，可能需要每天給新冠肺炎患者服用更大劑量的B2R拮抗劑幾次，以長期抑制病毒複製。
  • 價格行動：週二盤前交易時段，德意志銀行股價下跌1.62%，至14.58美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論